Immunome (IMNM) Non-Current Assets (2019 - 2026)
Immunome's (IMNM) quarterly Non-Current Assets came in at $25.5 million in Q1 2026, up 30.26% YoY from $19.6 million in Q1 2025, and up 13.71% on a QoQ basis from $22.4 million in Q4 2025.
Immunome (IMNM) Non-Current Assets (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Non-Current Assets data on file, last reported at $25.5 million in Q1 2026.
- Quarterly Non-Current Assets rose 30.26% year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.2 million (up 36.28% YoY) and the FY2025 annual result came in at $22.4 million, up 18.56% from the prior year.
- Non-Current Assets advanced to $25.5 million in Q1 2026, from $22.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $25.5 million in Q1 2026 to a low of $1.3 million in Q3 2022.
- A 5-year average of $10.0 million and a median of $6.4 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 4.46% — and 2024, when it soared 636.0%.
- Tracing IMNM's Non-Current Assets over 5 years: stood at $1.4 million in 2022, then surged by 174.66% to $3.8 million in 2023, then soared by 392.62% to $18.9 million in 2024, then grew by 18.56% to $22.4 million in 2025, then rose by 13.71% to $25.5 million in 2026.
- The last three Non-Current Assets figures came in at $25.5 million (Q1 2026), $22.4 million (Q4 2025), and $19.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 26.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.94 Mn |
| Mar 31, 2026 | 25.48 Mn |
| Dec 31, 2025 | 22.41 Mn |
| Sep 30, 2025 | 19.45 Mn |
| Jun 30, 2025 | 18.86 Mn |
| Mar 31, 2025 | 19.56 Mn |
| Dec 31, 2024 | 18.90 Mn |
| Sep 30, 2024 | 12.86 Mn |
| Jun 30, 2024 | 11.93 Mn |
| Mar 31, 2024 | 6.43 Mn |
| Dec 31, 2023 | 3.84 Mn |
| Sep 30, 2023 | 1.75 Mn |
| Jun 30, 2023 | 1.91 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 1.31 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 1.37 Mn |